Last reviewed · How we verify
RSS0343 tablets
At a glance
| Generic name | RSS0343 tablets |
|---|---|
| Sponsor | Reistone Biopharma Company Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease (PHASE2)
- A Clinical Study of RSS0343 in Healthy Subjects (PHASE1)
- Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RSS0343 Tablets in Healthy Subjects After Single and Multiple Oral Administration and the Effect of Food on the Pharmacokinetics of RSS0343 (PHASE1)
- Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSS0343 tablets CI brief — competitive landscape report
- RSS0343 tablets updates RSS · CI watch RSS
- Reistone Biopharma Company Limited portfolio CI